Please use this identifier to cite or link to this item: https://doi.org/10.1182/blood-2012-08-450494
Title: EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
Authors: Yan, J. 
Ng, S.B.
Tay, J.L.
Lin, B.
Koh, T.L.
Tan, J.
Selvarajan, V.
Liu, S.C.
Bi, C.
Wang, S.
Choo, S.N.
Shimizu, N.
Huang, G.
Yu, Q.
Chng, W.J.
Issue Date: 30-May-2013
Citation: Yan, J., Ng, S.B., Tay, J.L., Lin, B., Koh, T.L., Tan, J., Selvarajan, V., Liu, S.C., Bi, C., Wang, S., Choo, S.N., Shimizu, N., Huang, G., Yu, Q., Chng, W.J. (2013-05-30). EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.. Blood 121 (22) : 4512-4520. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2012-08-450494
Abstract: The role of enhancer of zeste homolog 2 (EZH2) in cancer is complex and may vary depending on the cellular context. We found that EZH2 is aberrantly overexpressed in the majority of natural killer/T-cell lymphoma (NKTL), an aggressive lymphoid malignancy with very poor prognosis. We show that EZH2 upregulation is mediated by MYC-induced repression of its regulatory micro RNAs and EZH2 exerts oncogenic properties in NKTL. Ectopic expression of EZH2 in both primary NK cells and NKTL cell lines leads to a significant growth advantage. Conversely, knock-down of EZH2 in NKTL cell lines results in cell growth inhibition. Intriguingly, ectopic EZH2 mutant deficient for histone methyltransferase activity is also able to confer growth advantage and rescue growth inhibition on endogenous EZH2 depletion in NKTL cells, indicating an oncogenic role of EZH2 independent of its gene-silencing activity. Mechanistically, we show that EZH2 directly promotes the transcription of cyclin D1 and this effect is independent of its enzymatic activity. Furthermore, depletion of EZH2 using a PRC2 inhibitor 3-deazaneplanocin A significantly inhibits growth of NK tumor cells. Therefore, our study uncovers an oncogenic role of EZH2 independent of its methyltransferase activity in NKTL and suggests that targeting EZH2 may have therapeutic usefulness in this lymphoma.
Source Title: Blood
URI: http://scholarbank.nus.edu.sg/handle/10635/116343
ISSN: 15280020
DOI: 10.1182/blood-2012-08-450494
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

41
checked on May 24, 2018

WEB OF SCIENCETM
Citations

43
checked on May 16, 2018

Page view(s)

48
checked on May 11, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.